跳至主要内容
临床试验/NCT05001646
NCT05001646Unknown2 期

Clinical and Molecular Impact of In-home Resonance-based Electromagnetic Field Protection Device Usage in Healthy Individuals

TruDiagnostic0 个研究点目标入组 44 人开始时间: 2022年3月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
发起方
入组人数
44
主要终点
Epigenetic Testing

研究概览

简要总结

This is a prospective, single group, self-controlled study to evaluate the clinical and molecular impact of continuous in-home resonance-based electromagnetic field (EMF) protection device usage in healthy individuals.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Any sex, gender orientation, and ethnicity
  • •Between ages 30 and 70
  • •Must be willing and able to participate in venipuncture, health history and clinical assessments, passive monitoring (Oura ring), and continuous in-home Blushield device usage

排除标准

  • •Significant change in diagnosis and/or treatment of major illness or injury within 2 years prior to screening, e.g., diabetes, cancer, cardiovascular disease, psychiatric condition
  • •Any ongoing immune system concerns or immunodeficiency disease
  • •History of any viral illness in preceding year
  • •Body mass index (BMI) > 35 kg/m2
  • •Presence of active infection
  • •Any other illness, disorder, alcohol or chemical dependence that in the opinion of investigators would render study participation unsuitable
  • •Unable or unwilling to provide required biological sample
  • •Unable or unwilling to avoid pregnancy during study period

研究组 & 干预措施

In-home EMF protection device

Experimental

干预措施: In-home resonance-based electromagnetic field protection device (Device)

结局指标

主要结局

Epigenetic Testing

时间窗: Change from baseline to 12 weeks

次要结局

未报告次要终点

研究者

发起方
TruDiagnostic
申办方类型
Industry
责任方
Sponsor

相似试验